Detalles de la búsqueda
1.
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
Future Oncol
; 2022 Jul 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35852104
2.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 261-270, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838015
3.
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer
; 126(2): 432-443, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31581306
4.
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Cancers (Basel)
; 16(8)2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38672547
5.
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
J Clin Oncol
; 40(26): 3065-3076, 2022 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35442766
Resultados
1 -
5
de 5
1
Próxima >
>>